Evidence map›Paper›PMID 25730868›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression.

Daniel T Claiborne, Jessica L Prince, Eileen Scully, Gladys Macharia, Luca Micci, Benton Lawson, Jakub Kopycinski, Martin J Deymier, Thomas H Vanderford, Krystelle Nganou-Makamdop and 15 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 105 citations in OpenAlex.

  1. Neuroimmune Correlates of HIV and Marijuana Use: Peripheral Biomarkers and Cognitive Function.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 3 countries.

Daniel T ClaiborneEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
Jessica L PrinceEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
Eileen ScullyRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139;
Gladys MachariaHuman Immunology Laboratory, International AIDS Vaccine Initiative, London SW10 9NH, United Kingdom;
Luca MicciEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
Benton LawsonEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
Jakub KopycinskiHuman Immunology Laboratory, International AIDS Vaccine Initiative, London SW10 9NH, United Kingdom; Faculty of Medicine, Imperial College, London SW7 2AZ, United Kingdom;
Martin J DeymierEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
Thomas H VanderfordEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
Krystelle Nganou-MakamdopVaccine Research Center, National Institutes of Health, Bethesda, MD 20817;
Zachary EndeEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
Kelsie BrooksEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
Jianming TangDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294;
Tianwei YuDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, GA 30322;
Shabir LakhiZambia-Emory HIV Research Project, Lusaka, Zambia;
William KilembeZambia-Emory HIV Research Project, Lusaka, Zambia;
Guido SilvestriEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
Daniel DouekVaccine Research Center, National Institutes of Health, Bethesda, MD 20817;
Paul A GoepfertDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294;
Matthew A PriceEpidemiology Unit, International AIDS Vaccine Initiative, San Francisco, CA 94143; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94143;
Susan A AllenZambia-Emory HIV Research Project, Lusaka, Zambia; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322; Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322; and.
Mirko PaiardiniEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
Marcus AltfeldRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139; Virus Immunology Unit, Heinrich-Pette-Institut, 20251 Hamburg, Germany.
Jill GilmourHuman Immunology Laboratory, International AIDS Vaccine Initiative, London SW10 9NH, United Kingdom; Faculty of Medicine, Imperial College, London SW7 2AZ, United Kingdom;
Eric HunterEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322; ehunte4@emory.edu.
Emory University · USInternational AIDS Vaccine Initiative · USNational Institutes of Health · USUniversity of Alabama at Birmingham · USInternational HIV/AIDS Alliance · GBLeibniz Institute of Virology (LIV) · DERagon Institute of MGH, MIT and Harvard · USUniversity of California, San Francisco · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 1985 to 2011
$114.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
CTL and HIV Polymorphisms in Heterosexual TransmissionR01AI064060 · NIAID · EMORY UNIVERSITY · PI GOEPFERT, PAUL A., HUNTER, ERIC · 2005 to 2019
$21.7M
Host Genomic Factors in Infectious Disease Susceptibility ZIAAI005066 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$17.9M
Virologic Correlates of Heterosexual TransmissionR37AI051231 · NIAID · EMORY UNIVERSITY · PI HUNTER, ERIC · 2008 to 2017
$9.6M
NCRR NIH HHS 2P51RR000165-51NCRR NIH HHS P51 RR000165NCRR NIH HHS P51RR165NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI064060NIAID NIH HHS R01 AI64060NIAID NIH HHS R37 AI051231NIAID NIH HHS R37 AI51231NIH HHS OD P51OD11132NIH HHS P51 OD011132
6 · The paper itself

Abstract

HIV-1 infection is characterized by varying degrees of chronic immune activation and disruption of T-cell homeostasis, which impact the rate of disease progression. A deeper understanding of the factors that influence HIV-1-induced immunopathology and subsequent CD4(+) T-cell decline is critical to strategies aimed at controlling or eliminating the virus. In an analysis of 127 acutely infected Zambians, we demonstrate a dramatic and early impact of viral replicative capacity (vRC) on HIV-1 immunopathogenesis that is independent of viral load (VL). Individuals infected with high-RC viruses exhibit a distinct inflammatory cytokine profile as well as significantly elevated T-cell activation, proliferation, and CD8(+) T-cell exhaustion, during the earliest months of infection. Moreover, the vRC of the transmitted virus is positively correlated with the magnitude of viral burden in naive and central memory CD4(+) T-cell populations, raising the possibility that transmitted viral phenotypes may influence the size of the initial latent viral reservoir. Taken together, these findings support an unprecedented role for the replicative fitness of the founder virus, independent of host protective genes and VL, in influencing multiple facets of HIV-1-related immunopathology, and that a greater focus on this parameter could provide novel approaches to clinical interventions.

Indexed as

Virus ReplicationCD4 Lymphocyte CountCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCohort StudiesCytokinesDisease ProgressionFemaleHIV-1HIV InfectionsHomeostasisHumansImmunologic MemoryInflammationKaplan-Meier EstimateLymphocyte ActivationCytokinesGagHIV-1immune activationpathogenesisreplicative capacity

Identifiers

PMID25730868
PMCPMC4378387
OpenAlexW2094193440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.